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SKAR Is a Specific Target of S6 Kinase 1
in Cell Growth Control
refocused attention to the role that misregulated cell
growth plays in the development of tumors [2].
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priate to the extracellular environment. A central playerHarvard Medical School
Boston, Massachusetts 02115 in cell growth control is the target of rapamycin, TOR
(also known as FRAP, RAFT1, and RAPT), a serine/threo-2 Aventis Pharma
DI&A Chemistry nine protein kinase that is responsive to nutrient, energy,
and mitogenic stimuli [3]. A major breakthrough in our65926 Frankfurt
Germany understanding of how TOR is regulated came from the
discovery that it is inhibited by a tumor suppressor com-3 Charite Children’s Hospital
Humboldt University plex, comprised of the Tuberous Sclerosis Complex pro-
teins TSC1 and TSC2. TSC2 links TOR to the mitogen-13353 Berlin
Germany sensing phosphoinositide 3-kinase (PI3K) signaling
pathway, as Akt (which is activated by PI3K) phosphory-
lates and inactivates TSC2. Furthermore, TSC2 regu-
lates the ability of TOR to sense cellular energy levels, asSummary
the AMP-activated and LKB1-dependent kinase, AMPK,
phosphorylates and activates TSC2 to reduce TOR ac-Background: The mammalian target of rapamycin
tivity when cellular energy levels are limiting. Finally,(mTOR) and phosphatidylinositol 3-kinase (PI3K) signal-
TOR has been linked to nutrient sensing through theing pathways promote cell growth and cell cycle pro-
Ras-like GTPase, Rheb, which is in turn regulated by thegression in response to nutritional, energy, and mito-
GTPase-activating protein (GAP) activity of the TSC1/2genic cues. In mammalian cells, the ribosomal protein
complex. The importance of TOR and cell growth inS6 kinases, S6K1 and S6K2, lie downstream of mTOR
the development of tumors is revealed by its positionand PI3K, suggesting that translational control through
downstream of the tumor suppressors TSC1, TSC2,the phosphorylation of S6 regulates cell growth. Inter-
LKB1, and PTEN and by the emerging success of theestingly, genetic experiments predict that a substrate
TOR inhibitor rapamycin and its analogs against cancersthat is specific to S6K1 but not S6K2 regulates cell
resulting from misregulation of the PI3K pathway [4].growth.
The ribosomal protein S6 kinase (S6K) family mem-Results: Here we identify SKAR as a novel and specific
bers, dS6K in Drosophila and S6K1 in mammals, arebinding partner and substrate of S6K1 but not S6K2.
important downstream targets of TOR and PI3K in cellWe find that serines 383 and 385 of human SKAR are
and organism growth control. In Drosophila, mutationinsulin-stimulated and rapamycin-sensitive S6K1 phos-
of dS6K results in a high incidence of lethality, develop-phorylation sites. Quantitative mass spectrometry re-
mental delay, and, in surviving flies, a decrease in theveals that serine 383/385 phosphorylation is sensitive
size of the whole organism and individual cells [5]. Con-to RNA interference (RNAi)-mediated S6K1 reduction,
sistent with dS6K mutant fly phenotypes, knockout ofbut not S6K2 reduction. Furthermore, RNAi-mediated
S6K1 in mice results in small organism size and develop-reduction of SKAR decreases cell size. SKAR is nuclear
mental delay [6]. These mice are mildly glucose intoler-protein with homology to the Aly/REF family of RNA
ant and hypoinsulinemic and show a reduction in pan-binding proteins, which has been proposed to couple
creatic  cell size [7]. In mammalian tissue culture cells,transcription with pre-mRNA splicing and mRNA export.
treatment with drugs that prevent activation of S6K1,Conclusions: We have identified a novel and specific
including the mTOR inhibitor rapamycin or the PI3K in-target of S6K1, SKAR, which regulates cell growth. The
hibitor LY294002, results in decreased cell size [8]. Con-homology of SKAR to the Aly/REF family links S6K1 with
versely, overexpression of S6K1 induces a shift to largermRNA biogenesis in the control of cell growth.
cell size [8], and expression of an activated allele of S6K1
leads to skeletal muscle cell hypertrophy [9]. These data
Introduction implicate S6K1 in cell-autonomous growth as well as
organism growth control.
The recent revival of attention to the cellular process of It is currently thought that the TOR and PI3K signaling
growth, i.e., an increase in cell size and mass, is lending pathways drive cell growth by increasing the transla-
greater depth to our understanding of cell proliferation. tional capacity of the cell [10]. In mammalian cells, the
Cell division is normally coordinated with cell growth to mTOR and PI3K pathways lead to the activation S6K1
ensure that proliferating cells maintain a given charac- and S6K2, which phosphorylate the 40S ribosomal sub-
teristic size after division [1]. Abnormal proliferation, for unit protein S6 (S6) [3]. S6 phosphorylation is thought
example in cancer, is widely recognized as a defect to enable the translation of mRNAs containing a repres-
in cell division control. However, recent studies have sive 5 terminal oligo-pyrimidine sequence (5TOP),
which largely encode components of the translation ap-
paratus itself [11]. Recently, this model has come into*Correspondence: jblenis@hms.harvard.edu
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question due to the lack of a strict correlation between
S6 phosphorylation and 5TOP mRNA translation [12–14].
Interestingly, the degree of S6 phosphorylation in
S6K1 knockout mice is comparable to that in wild-type
mice, suggesting that the highly homologous S6K2 (70%
percent overall identity and 85% similarity) is compen-
sating enzymatically for the lack of S6K1 [6]. Surpris-
ingly, knockout of S6K2 results in no defects in cell or
organism size, despite a reduction in S6 phosphorylation
[14]. Collectively, these results imply that the small
mouse phenotype is unique to disruption of the S6K1
allele and does not derive from a lack of S6 phosphoryla-
tion. Furthermore, the S6K1 phenotype predicts that
there exist targets of S6K1 important for organism size
control upon which S6K2 does not act. Although several
new S6K1 substrates have been reported [3], none has
been shown to be specific to S6K1 or to be involved in
cell growth control. Hence the question remains: how
does S6K1 regulate cell growth?
We report here the isolation of a novel protein, SKAR
(for S6K1 Aly/REF-like target), which interacts with and
is a substrate of S6K1 but not S6K2. SKAR shares se-
quence homology with members of the Aly/REF family
of RNA binding proteins, which couple transcription,
pre-mRNA splicing, and nucleo-cytoplasmic mRNA
transport [15]. SKAR is phosphorylated by S6K1 in vitro
on sites that are mitogen regulated and rapamycin sensi-
tive in vivo. RNA interference (RNAi)-mediated reduction
of S6K1 but not S6K2 reduces the amount of SKAR
phosphorylation, as determined by quantitative mass
spectrometry. Decreasing SKAR or S6K1 levels by RNAi
makes cells smaller, suggesting that SKAR is a target
of S6K1 in cell growth control. These data suggest that
cell growth regulation by the mTOR and PI3K pathways
involves more than just translational control but may
also impinge on the mRNA biosynthetic machinery.
Results
Isolation of a Predicted RNA Binding Protein
that Interacts with S6K1 and Not S6K2
To identify novel targets of S6K1, we performed two-
hybrid screening of a mouse embryonic library [16] and
Figure 1. Isolation of a Novel S6K1-Specific Targetobtained three clones encoding the same protein (Figure
(A) Clone 49 from two-hybrid screening or vector control was trans-1B) that interacted with the full-length wild-type S6K1
formed into yeast with plasmids bearing the indicated GAL4 DNAbait (Figure 1A). We tested one of these, clone 49, for
binding domain fusions and grown on minimal media lacking uracil,specificity of interaction with different domains of S6K1 leucine, and adenine to select for two-hybrid interaction. The sche-
or S6K2 (Figure 1A). S6K1NT/CT contains a deletion matic shows the domains (catalytic, linker, or pseudosubstrate
of the N and C termini, leaving only the catalytic and [p.s.]) contained in S6K1-wild-type (WT), NT/CT (amino acids [aa]
27–402; aa 31–401 of S6K2), and C-Term (aa 403 to the C terminus).linker domains (regions critical for catalysis and for acti-
(B) The partial SKAR clones (49, 102, and 42) obtained from the two-vation of the kinase through multisite phosphorylation)
hybrid mouse library are schematically aligned with the two full-[17]. Clone 49 interacted more strongly with S6K1NT/
length human clones (isoforms  and ). The position of the RNACT than with full-length S6K1, but surprisingly, did not recognition motif is indicated (RRM).
interact with S6K2NT/CT, despite greater than 80% (C) The sequence of full-length SKAR (isoform ) is shown. Amino
amino acid identity between S6K1 and S6K2 in this re- acids absent in isoform  are italicized. The predicted RNA binding
domain is underlined. The repeated DARXK/RI/L (X any amino acid)gion. Additional S6K1 interactors obtained in this screen
motifs are highlighted in boldface.did interact with S6K2NT/CT, indicating that this con-
struct is functional (data not shown). Clone 49 did not
interact with the S6K1 C terminus, further confirming
the specificity of the interaction. Together, these data Sequence database searches reveal clone 49 to be a
partial clone (Figure 1B) of a mouse gene with a humanshow that binding of SKAR to S6K1 is mediated by the
S6K1 catalytic and/or linker domains. ortholog of unknown function on chromosome 22,
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PDIP46, which has been reported to interact by two- SKAR Coimmunoprecipitates Activated
S6K1 but Not S6K2hybrid assay with DNA polymerase  (no further func-
The binding of SKAR to the S6K1-NTCT mutant in thetional data were reported) [18]. The encoded protein
two-hybrid assay (Figure 1A) and the hyperphosphory-contains an RNA recognition motif (RRM) [19], with high-
lated form of S6K1 in the GST pull-down assay (Figureest homology to the Aly/REF family of RNA binding pro-
3A) suggests that SKAR recognizes a domain of acti-teins (42% identity, 57% similarity in the RRM). There-
vated S6K1 that is exposed upon phosphorylation (or,fore, we have termed this protein SKAR for S6K1 Aly/
artificially, truncation) of S6K1. To test whether SKARREF-like target. In addition to homology in the RRM, the
interacts with activated S6K1 in vivo, we performedN-terminal 11 amino acids are highly conserved (57%
coimmunoprecipitation experiments. We cotransfectedidentity, 78% similarity) with the N terminus of Aly/REF,
HEK293E cells with HA-tagged S6K1 and GST-taggeda region shown to be important for Aly/REF function
clone 49, immunoprecipitated S6K1 using anti-HA anti-[20]. We cloned two full-length splice variants of human
bodies, and detected association of clone 49 by WesternSKAR (Figure 1B) encoding proteins with predicted
blotting with anti-GST antibodies. We detected insulin-masses of 46 kDa (isoform ) (Figure 1C) and 43 kDa
stimulated and rapamycin-sensitive interaction between(isoform ). Although we do not currently understand
the clone 49 fragment of SKAR and wild-type S6K1 andits significance, we have noticed a series of six
constitutive association between the constitutively acti-DARXK/RI/L (X  any amino acid) motifs within the N-ter-
vated S6K1 mutant ED3E, which has serine and threo-minal region of SKAR. Database searches reveal SKAR
nine residues substituted by acidic amino acids to mimichomologs in mouse and rat with 91% amino acid identity
S6K1 phosphorylation [17, 21] (Figure 3B). We nextand a potential homolog in Drosophila but not in lower
tested whether full-length Flag-tagged SKAR couldeukaryotes.
bind to HA-tagged S6K1 by coimmunoprecipitation. We
could not consistently detect an interaction above back-
ground between full-length SKAR and wild-type S6K1SKAR Is Widely Expressed and Localizes
(data not shown), perhaps due to a transience of interac-to the Nucleus
tion between the two full-length proteins. If we expressSKAR is expressed in all tissues examined, with the
the constitutively activated ED3E mutant of S6K1, inter-highest levels in brain, heart, skeletal muscle, and kidney
action is detectible (Figure 3C; lanes 4–6). An even(Figure 2A). We assessed the intracellular localization of
stronger interaction is detectible with the S6K1 C-ter-SKAR by indirect immunofluorescence with anti-SKAR
minal truncation mutant, CT, in which the pseudosub-antibodies. SKAR staining is nuclear, residing both in the
strate autoinhibitory domain, which is thought to oc-nucleoplasm and in punctate structures, and is excluded
clude the catalytic domain of inactive S6K1, is deletedfrom nucleoli (Figure 2B). In mitotic cells, SKAR is cyto-
[17] (Figure 3C; lanes 7–9). Although the phosphorylationplasmically localized (upper middle panel, cell on the
of S6K1CT is regulated by insulin and rapamycin treat-right-hand side). Serum starvation, serum stimulation,
ment of cells [21–23], interaction with SKAR is not, sug-rapamycin treatment, or stress such as heat or osmotic
gesting that SKAR recognizes the open conformationshock do not alter the localization of SKAR (data not
of S6K1 rather than particular phosphorylated residues.shown). Similar staining is seen in U2OS, NIH3T3, and
We next tested whether SKAR could bind S6K2 in vivo.HeLa cells and in cells transfected with 3xHA-tagged
Because we saw strong binding between the S6K1CTSKAR and stained with anti-HA antibodies (data not
mutant and SKAR, we tested whether we could coimmu-
shown).
noprecipitate the equivalent mutant of S6K2. Under con-
ditions where we saw binding of SKAR to S6K1CT, we
saw no binding to S6K2CT (Figure 3D) or to S6K2 wild-
The RRM Region of SKAR Binds Specifically
type (data not shown).
to the Hyperphosphorylated Form of S6K1
To confirm the two-hybrid interaction of S6K1 with SKAR SKAR Is a Substrate of S6K1 but Not S6K2
by using a GST pull-down assay, we incubated a GST- Using immune-complex kinase assays, we determined
fusion protein of clone 49 bound to glutathione Sepha- that SKAR is phosphorylated by S6K1 and S6K1CT,
rose beads with lysates from serum-starved or insulin- but not by a kinase inactive mutant of S6K1 (K/R) (Figure
stimulated HEK293E cells, conditions that inactivate and 4A). The activity of S6K1 toward SKAR mirrors the activ-
activate S6K1, respectively. When the mTOR and PI3K ity toward S6, i.e., it is low when S6K1 is isolated from
pathways are activated in cells by nutrients and mito- serum-starved cells and high when S6K1 is isolated
gens, S6K1 undergoes multisite phosphorylation lead- from insulin-stimulated cells. In contrast, S6K2 did not
ing to its activation [10]. Clone 49 specifically binds to phosphorylate SKAR under conditions where it phos-
the hyperphosphorylated form, i.e., the slowest migrat- phorylated S6 (Figure 4A). Since we have shown that
ing band, of both the predominantly cytoplasmic (p70) S6K2 is unable to bind to SKAR (Figures 1A and 3D),
and the nuclear (p85) isoforms of S6K1 from cells treated these data support a model whereby phosphorylation
with insulin (Figure 3A). The RRM-containing portion of of SKAR requires binding of SKAR to S6K1.
clone 49 (49-C), but not the N-terminal portion (49-N),
is sufficient for S6K1 binding. The interaction is insensi- S6K1 Requires Docking to the RRM
tive to RNase treatment, suggesting that RNA does not of SKAR for Phosphorylation
coordinate binding between the two proteins (data not To narrow down the site of phosphorylation, we tested
the ability of S6K1 to phosphorylate various deletionshown).
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Figure 2. SKAR Is Widely Expressed and Lo-
calizes to the Nucleus
(A) Human multiple tissue Northern blot
(Clontech) probed with a 32P-labeled restric-
tion fragment of human SKAR. Kilobase mark-
ers are shown on the left. An arrow indicates
the position of the SKAR transcript. P.B.L. is
peripheral blood leukocytes.
(B) Indirect immunofluorescence of U2OS
cells stained with anti-SKAR antibodies (top
row, middle and right panels) or with anti-
SKAR antibodies preincubated with immuniz-
ing peptide (bottom right). Nuclei are shown
with DAPI staining (left panels). An enlarge-
ment of two cells stained with anti-SKAR anti-
bodies is shown (top right).
mutants of SKAR (Figures 4B and 4C). The N-terminal S275, S383, S385, and S405/406 (Table 1). Because we
(amino acids 1–190), the central (amino acids 191–357, also identified S383 and S385 as S6K1 phosphorylation
containing the RRM), and the C-terminal (amino acids sites in vitro, we tested whether the phosphorylation
358–421) portions of SKAR were not individually phos- state of S383 and S385 correlates with the activity of
phorylated by S6K1. However, S6K1 phosphorylated S6K1 in cells, i.e., is growth factor responsive and rapa-
SKAR when either the N terminus or the C terminus was mycin sensitive. We employed two-dimensional phos-
combined with the central portion (amino acids 1–357 pho-peptide mapping for this analysis. One peptide from
and 191–421, respectively). Combining just the S6K1 SKAR (spot 5) is significantly phosphorylated in re-
binding region in the RRM (as defined in Figure 3A) with sponse to insulin and dephosphorylated with rapamycin
the C terminus (amino acids 277–421) is sufficient for treatment and serum starvation (Figure 5A). The phos-
phosphorylation. These data reveal that the RRM serves phorylation state of the other four SKAR phospho-pep-
as a docking site for S6K1, mediating phosphate transfer tides is not significantly affected by these treatments.
to a distal site. To determine the S6K1 phosphorylation Phosphorylation of the insulin-regulated peptide is dra-
sites in the C terminus of SKAR, we performed mutational matically reduced in the SKAR-S385A mutant (Figure
analysis of a candidate S6K1 phosphorylation motif (Figure 5A) and in the SKAR-S383A mutant (Supplemental Fig-
4D). Mutation of either serine 383 or 385 in this motif to ure S2). Mass spectrometry reveals phosphorylation at
alanine resulted in reduced phosphorylation and mutation S383 and at S385, but not simultaneous phosphorylation
of both abolished phosphorylation, indicating that these at both S383 and S385 (Supplemental Figure S3). The
sites are phosphorylated by S6K1 in vitro. simplest interpretation of these results is that SKAR can
be phosphorylated either at S383 or at S385, but not
both, and that mutation of either serine residue affectsPhosphorylation of SKAR In Vivo
the ability of S6K1 to recognize the nonmutated serineEmploying mass spectrometry, we identified several
in vivo phosphorylation sites in SKAR, at residues S127, residue as a phosphorylation site.
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Figure 3. SKAR Binds to S6K1 In Vivo
(A) GST fusions of clone 49 (aa 191–357 rela-
tive to full-length SKAR), 49-N (aa 218–276),
and 49-C (aa 277–357; containing the RRM
as shown) bound to glutathione Sepharose
beads were incubated with lysate from 293
cells that were either starved () or stimulated
with insulin (ins). Beads were pelleted and
washed, and S6K1 was detected with anti-
S6K1 antibodies (p70 and p85 isoforms are
indicated). Lysate: 1/10 volume of the input
lysate.
(B) GST-tagged clone 49 (in the plasmid
pEGB) was cotransfected either with vec-
tor control, HA-S6K1-WT (p70 isoform), or
HA-S6K1-ED3E (containing T389E, S411D,
S418D, T421E, and S424D mutations). Cells
were starved and then either untreated (),
stimulated with insulin (ins), or treated with
rapamycin prior to insulin (rap). Cell lysates
were immunoprecipitated with anti-HA anti-
bodies. Immunoprecipitates were blotted
with anti-GST antibodies (upper panel) and
lysates were blotted with anti-HA antibodies
(middle panel) or anti-GST antibodies (lower
panel).
(C) Flag-tagged SKAR (isoform ) was co-
transfected either with vector control (lanes
1–3), HA-S6K1-ED3E (lanes 4–6), or S6K1CT
(lanes 7–9) in 293 cells. Immunoprecipitations
were performed as above. Immunoprecipi-
tates were blotted with anti-SKAR antibodies
(upper panel) or anti-HA antibodies (middle
panel). Lysates were blotted with anti-Flag
antibodies (lower panel). 1/10 volume of the
input lysate was run in lane 10.
(D) Coimmunoprecipitations were performed
as in (C), using vector control (lanes 1–3), HA-
S6K1CT (lanes 4–6), or HA-S6K2CT (lanes
7–9), and anti-HA immunoprecipitates were
blotted with anti-SKAR antibodies (upper
panel) or anti-HA antibodies (middle panel).
Lysates were blotted with anti-Flag antibod-
ies (lower panel). 1/20 volume of the input
lysate was run in lane 10.
To address whether SKAR is specifically a substrate data provide strong evidence that SKAR is a physiologi-
cal substrate of S6K1, but not S6K2.of S6K1 and not S6K2 in vivo, we employed quantitative
mass spectrometry. To quantitate phosphorylation of
SKAR on S383 or S385, we mixed isotope (13C/15N)- SKAR Regulates Cell Growth
S6K1 has been proposed to regulate cell growth be-labeled synthetic SKAR peptide standards of known
quantity with SKAR purified from cells, and we gener- cause deletion of S6K in Drosophila [5] and mice [6]
results in a small organism, and overexpression of S6K1ated peptides by trypsin digestion for mass spectrome-
try analysis [24]. The level of S383/385 phosphorylation in cell culture increases cell size [8]. To determine whether
SKAR regulates cell growth, we tested the effect of re-of SKAR isolated from insulin-stimulated cells is 5% 
1% and is reduced to 1.6% 0.2% by rapamycin (Figure ducing endogenous SKAR levels using RNAi. We used
U2OS osteosarcoma cells because they are transfect-5B), consistent with our phospho-peptide mapping re-
sults (above). We employed RNA intereference (RNAi) able with synthetic small interfering RNA (siRNA) and
the size of the cell population is relatively homogeneous.to reduce the levels of S6K1 or S6K2 in cells (Figure
5C, inset) and measured the effect on SKAR S383/385 Because the size of cells changes during passage
through the cell cycle, we measured the size of G1 phasephosphorylation. RNAi targeting S6K1 leads to a de-
crease of S383/385 phosphorylation, varying between cells using a flow cytometer with the parameter forward
scatter. We transfected cells with a control siRNA (con-20% and 60% in different experiments, compared to
control nonspecific RNAi. In the series displayed in Fig- taining the inverse sequence of the SKAR siRNA), siRNA
targeting S6K1, or siRNA targeting SKAR, and we mea-ure 5C, 1.3% 0.2% phosphorylation was observed for
the S6K1 RNAi-targeted sample, compared to 3.0%  sured the size of cells after 96 hr to allow sufficient time
for RNAi to take effect and for changes in cell size to0.7% for the control. In contrast, SKAR phosphorylation
is not reduced by RNAi targeting S6K2. In total, these occur. Reduction of S6K1 protein by targeting both the
SKAR Regulates Cell Growth
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Figure 4. SKAR Phosphorylation by S6K1
In Vitro
(A) HA-S6K1 (WT, CT, or kinase inactive
(K/R)), HA-S6K2 (WT or CT), or vector con-
trol (no kinase) were transfected into 293 cells
and immunoprecipitated from starved () or
insulin-treated (ins) cells for immune-com-
plex kinase assays using GST-SKAR (top
panel) or GST-S6 (middle panel) as sub-
strates. Upper and middle panels: autoradio-
gram showing phosphorylation. Bottom panel:
anti-HA Western blot showing expression
levels of the transfected kinases. S6K2 WT
and CT were cotransfected with PDK1 and
PKC-zeta to obtain maximal activity [38].
(B) Schematic of truncation mutants of SKAR
prepared as GST-fusion proteins, purified
from bacteria, and used as substrates in an
immune complex kinase assay. The RRM and
S6K1 binding domain is indicated.
(C) S6K1 was immunoprecipitated from
starved () or insulin-stimulated (	) cells and
used in an immune complex kinase assay as
in (A). The SKAR truncation mutants (shown
in [B]) or S6 control were tested as substrates.
Phosphate incorporation is shown by autora-
diography.
(D) The SKAR C-terminal phosphorylation site
was mapped by mutating the indicated ser-
ines to alanine. GST-fusions of mutants in the
context of SKAR amino acids 277 to 421 were
tested as substrates for S6K1 as in (C).
p70 and p85 isoforms with siRNA decreases cell size since we see a decreased rate of passage through S
phase as measured by bromodeoxyuridine (BrdU) incor-relative to cells treated with the control siRNA (Figures
6A, left, and 6B). Reduction of SKAR likewise decreases poration (Table 2).
cell size (Figures 6A, right, and 6B). Western blotting
indicates that the knockdown of S6K1 and SKAR is not Discussion
complete (Figure 6C), suggesting that the effects on cell
size shown are an underestimate of the potency of these We report here the identification of SKAR, a novel bind-
ing partner and substrate for S6K1. SKAR binds thegenes. The observed decreases in size do not appear
to occur because of a faster rate of passage through activated, hyperphosphorylated form of S6K1. Binding
occurs within the catalytic and/or linker domains ofthe cell cycle permitting insufficient time for cell growth,
Table 1. Phosphorylation Sites in SKAR Detected by Mass Spectrometry
Peptide Position Modified Residue Peptide Sequence Sequest Xcorr Valuea
126–144 127 SS*PAAFINPPIGTVTPALK 4.08 (2)
266–281 275 ELPAAEPVLS*PLEGTK 3.36 (2)
381–400 383b VNS*ASSSNPPAEVDPDTILK 3.32 (2)
381–400 385b VNSAS*SSNPPAEVDPDTILK 3.18 (2)
405–418 405/406c S(*)S(*)GASVTTQPTEFK 2.18 (2)
a Charge state given in parentheses.
b Fragments indicative of phosphorylation at both S383 and S385 are observed.
c A distinction between the indicated sites is not possible from MS data.
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Figure 5. SKAR Phosphorylation In Vivo
(A) Two-dimensional phosphopeptide maps
are shown of transfected Flag-SKAR isolated
from 293 cells metabolically labeled with
[32P]orthophosphate and either serum starved
(Starved), starved and then insulin treated (In-
sulin), or starved and then rapamycin treated
and then insulin treated (Rapamycin 	 In-
sulin) or of transfected Flag-SKAR-S385A
from starved and then insulin-treated cells
(S385A 	 Insulin). The position of the origin,
the direction of electrophoresis, and the di-
rection of chromatography are indicated.
(B) Flag-SKAR was transfected and cells were
serum-starved for 24 hr, then stimulated with
insulin for 30 min (ins) or treated with rapa-
mycin for 30 min prior to insulin stimulation
(rap). Flag-SKAR was immunoprecipitated
from cells, purified by SDS-PAGE, and in-gel
digested with trypsin, and the generated pep-
tides spanning S383/385 were quantified by
LC/MS/MS with internal reference standards.
The percent of phosphorylated S383 and/or
S385 peptide relative to dephosphorylated
peptide is shown.
(C) Cells were cotransfected with Flag-SKAR
and control, S6K1, or S6K2 RNAi-generating
plasmids (pBS/U6-based), as indicated. Cells
were serum-starved for 24 hr after transfec-
tion, then stimulated with insulin for 30 min.
S383/385 phosphorylation was measured as
in (B). The error bars indicate the standard
deviation obtained for triplicate measure-
ments of a sample. Inset: Constructs were
tested for their ability to reduce S6K1 or S6K2
expression by cotransfection of 4.5 
g of
pBS/U6 vector or pBS/U6-S6K1 with 0.5 
g
of HA-tagged S6K1 (rat clone that has the
same nucleotide sequence as human in the
region targeted by RNAi) or 4.5 
g of pBS/
U6 vector or pBS/U6-S6K2 with 0.5 
g of HA-
tagged S6K2 (human clone) in HEK293 cells.
Cell lysates were prepared 48 hr after trans-
fection and blotted with anti-HA antibodies.
S6K1 and within the RRM of SKAR. The RRM is function- of S6K1 upon which S6K2 does not act. SKAR, being
an exclusive target of S6K1, may be a critical player ining as an S6K1 “docking site,” as S6K1 is unable to
phosphorylate SKAR without the SKAR RRM. Docking the function of S6K1 in cell and organism growth control.
Furthermore, SKAR may have particular importance insites, i.e., kinase binding modules mediating phosphate
transfer to distal sites, have been reported previously pancreatic  cell size determination and insulin secre-
tion, an exciting possibility for future investigation.for other kinases [25], but this is the first report of a
docking site for the S6 kinases. More precise definition The regulation of cell growth by components of the
mTOR and PI3K pathways is typically attributed to theof the docking site within the RRM of SKAR could ulti-
mately lead to the identification of additional binding effects of these pathways on translation [10, 26, 27].
One consequence of the activation of these pathwayspartners and substrates of S6K1.
This is the first report of a protein that is a specific is the phosphorylation of eukaryotic initiation factor 4E
(eIF-4E) binding proteins (4E-BPs), which function astarget of S6K1 but not S6K2, and SKAR is the first S6K1
substrate shown to have an effect on cell growth. We inhibitors of cap-dependent translation [26]. Also, down-
stream of mTOR and PI3K are S6K1 and S6K2, whichand others have shown a role for S6K1 in driving cell
size changes in cultured mammalian cells (Figure 6) [8, phosphorylate the ribosomal protein S6 [3]. S6 phos-
phorylation may enable the translation of mRNAs con-9]. The existence of an exclusive target for S6K1 in cell
growth control is supported by genetic evidence from taining a repressive 5TOP sequence, which largely en-
code components of the translational apparatus itselfS6K1 and S6K2 knockout mice studies [6]. S6K1-defi-
cient mice are smaller, have reduced pancreatic  cell [11], although this model of translational control is cur-
rently in dispute [12–14]. Recently, translation elonga-size, and are hypoinsulinemic, yet S6 phosphorylation
is normal [6, 7]. Conversely, knockout of S6K2 does not tion factor 2 kinase (eEF2k) was identified as an S6K1
substrate [28]. Phosphorylation of eEF2k leads to itsresult in a small mouse phenotype, despite reduced S6
phosphorylation [14]. Hence, there appear to be targets inactivation and thereby enables the dephosphorylated
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Figure 6. Reduction of SKAR Levels Makes
Cells Smaller
(A) Flow cytometry was used to obtain for-
ward scatter height (FSC-H) histograms of
U2OS cells transfected with siRNA oligonu-
cleotides targeting S6K1 (left, red) or SKAR
(right, green) or control (inverse of the SKAR
sequence; both panels, black). Cells were
transfected, grown for 48 hr, then retrans-
fected and grown for 24 hr to allow time for
RNA interference and changes in cell size to
occur. Shown is the FSC-H of G1 phase cells
of one representative transfection from which
10,000 cells were counted.
(B) Mean forward scatter height (FSC-H) of
G1 phase cells from triplicate siRNA transfec-
tions (one of which is shown in [A]) with stan-
dard deviation (error bars). The paired Stu-
dent’s t test was performed on all samples
compared to the control. All data is statisti-
cally significant (p  0.04).
(C) Levels of knockdown of SKAR (top) or S6K
(middle) relative to loading control (ERK) were
determined by Western blotting.
Ayerst) treatment was for 30 min, and insulin stimulation was forform of eEF2 to allow translation elongation to proceed.
30 min.In addition, the eukaryotic translation initiation factor
4B (eIF4B), which functions along with eIF4A to unwind
AntibodiesmRNA to facilitate ribosome binding, was found to be
For indirect immunofluorescence, anti-SKAR antibodies were raised
a substrate of both S6K1 and S6K2 [29]. Although 4E- in rabbits against a peptide containing the SKAR sequence MKKES
BP1 and its binding partner eIF4E have been shown to ELPRRVNSASS (Invitrogen), affinity purified, and used at a dilution
regulate cell size [8, 30–32], no target of the S6 kinases of 1:100. For Western blotting, anti-SKAR antibodies were raised in
rabbits against a peptide containing the N-terminal SKAR sequenceother than SKAR has been shown to influence cell size.
ADISLDELIRKRGAAAK (Invitrogen) and used at a dilution of 1:1000.The homology between SKAR and the Aly/REF family
Anti-HA monoclonal antibody from ascites fluid was a gift fromof proteins suggests that SKAR could have a function
Margaret Chou (University of Pennsylvania, Philadelphia, PA). Anti-
related to that of Aly/REF, i.e., the coupling of transcrip- Flag monoclonal antibody M2 was purchased from Sigma.
tion, splicing, and mRNA export [15]. Because SKAR
localizes to the nucleus, we do not anticipate a direct Western Blotting and Immunofluorescence
role for SKAR in translation control. Rather, we propose Cell lysates were prepared for Western blotting as in Romanelli et
al. [33]. Anti-S6K1 and anti-HA Western blots were performed as inthat SKAR functions like Aly/REF to regulate mRNA bio-
Martin et al. [38]. For immunofluorescence, U2OS cells were growngenesis. Through coupling transcription, splicing, and/
on coverslips, fixed with 3.7% formaldehyde, permeabilized withor export, SKAR could govern the biogenesis of tran-
0.2% Triton X-100, and stained with anti-SKAR primary antibodies,
scripts in response to S6K1 activation, ultimately leading followed by fluorescent-conjugated anti-rabbit secondary antibod-
to changes in cell growth. ies (Jackson ImmunoResearch Laboratories, Inc.) and DAPI. Cells
were visualized using a Nikon E800 upright epifluorescence micro-
Experimental Procedures scope. For peptide blocking, affinity purified anti-SKAR antibody
(10 
g) was preincubated with immunizing peptide (50 
g) for 1 hr
Cell Culture and Transfection prior to use.
Cells were cultured and transfected as in Romanelli et al. [33] for
HEK293E cells or as in Fingar et al. [8] for U2OS cells. Serum starva- GST Pull-Downs and Coimmunoprecipitation
tion was for 24 hr, rapamycin (provided by S.N. Seghal at Wyeth- GST pull-down assays and coimmunoprecipitations were performed
as in Chou et al. [34]. For coimmunoprecipitation, pCDNA3-Flag-
SKAR was cotransfected with pRK7 (vector control), HA-S6K1,
HA-S6K1E389D3E, HA-S6K1CT, HA-S6K2, or HA-S6K2CT intoTable 2. RNAi-Mediated Knockdown of S6K1 or SKAR Delays
HEK293E cells. Western blotting was performed with anti-SKARCell Cycle Progression
antibodies and HRP-conjugated protein A (ICN Biomedicals, Inc.)
siRNAa % BrdU-Positive Cellsb instead of secondary antibody to reduce detection of IgG.
control 55.5  2.2
Immune Complex Kinase AssaysS6K1 47.3  1.3
Kinase assays were performed as in Romanelli et al. [33]. SubstratesSKAR 43.8  1.1
for kinase assays were purified as GST-fusion proteins from bacteria
a U2OS were transfected with the indicated siRNA oligonucleotides using glutathione Sepharose.
as in Figure 6.
b Cells were incubated with BrdU for 1 hr, harvested, fixed, and
Two-Dimensional Phospho-Peptide Mappingstained with FITC-conjugated anti-BrdU antibody. BrdU incorpora-
HEK293E cells were transfected with Flag-SKAR, metabolicallytion was quantitated by flow cytometry. Data are the mean of tripli-
labeled with [32P]orthophosphate (ICN) for 2 hr, and then starved,cate transfections  standard error and are representative of three
stimulated with insulin, or rapamycin treated. SKAR was immuno-independent experiments.
precipitated with anti-Flag antibodies, purified by SDS-PAGE, and
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prepared for mapping as in Chen and Blenis [35]. Tryptic peptides BrdU- and PI-positive cells were detected by FACS [8]. The percent-
age of BrdU-positive cells equals the number of BrdU- (and PI-)(sequencing grade trypsin from Promega) were resolved first by
electrophoresis at pH 1.9, then by chromatography in phospho- positive cells divided by the total number of PI-positive cells. 10,000
cells were counted from each transfection.chromatography buffer [36]. Cells containing Flag-SKAR-S385A
were stimulated with insulin prior to lysis.
Supplemental Data
Two-hybrid screening, SKAR cloning, and plasmids are describedRNA Interference
in the Supplemental Data at http://www.current-biology.com/cgi/For mass spectrometry experiments, DNA plasmids expressing hair-
content/full/14/17/1540/DC1.pin RNA (see Supplemental Data for sequences) under the control
of the U6 promoter in pBS/U6 [37] were constructed to generate
RNAi targeting human S6K1 or S6K2. For cell size assays, synthetic Acknowledgments
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